arrow
W

Wanhong Zhao

Xi'an Jiaotong University
H指数:21
被引数:2,114

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of Nutritional and Immunological Scoring Systems Predicting Prognosis before Anti-B Cell Maturation Antigen Chimeric Antigen Receptor-T Therapy in Multiple Myeloma, a Retrospective Study Based on Legend-2

基于Legend-2的回顾性研究:比较预测多发性骨髓瘤患者接受抗B细胞成熟抗原嵌合抗原受体-T治疗前营养和免疫评分系统的预后价值

BLOOD
IF23.1
2024-11-050
PRE
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial

LCAR-B38M car-t细胞治疗后复发或难治性多发性骨髓瘤患者的长期缓解和生存: LEGEND-2试验的5年随访

2024-04-2410
OAAI
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
2023-07-277
OAAI
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

复发或难治性多发性骨髓瘤LCAR-B38M的4年随访: 中国1期、单臂、开放标签、多中心研究 (LEGEND-2)

2022-07-0685
OAAI
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

针对复发性或难治性多发性骨髓瘤患者的针对b细胞成熟抗原的嵌合抗原受体T细胞疗法LCAR-B38M的1期开放标签研究

2018-12-20424
OAAI